Nycomed’s Q2 Turnover Increases To E786.9m

Nycomed has reported sustained momentum in the second quarter of 2009, with total net turnover increasing by 0.5% to E786.9m for the first half of 2008. Adjusted EBITDA increased by 2.5% to E254.8m, when excluding the Sepracor payment. The gross profit for the company was E576m for the second quarter of 2009, as compared to E681.6m for the same period 2008.

For the six month ended period, the company reported net turnover of E1.62b, compared to E1.61b for the same period in 2008. The half yearly gross profit was E1.19b, compared to E1.29b for the same period of 2008. Adjusted EBITDA was E551.3m, as compared to E533.6m for the same period of 2008.

Hakan Bjorklund, CEO of Nycomed, said: The second quarter saw important advances in our pipeline. Daxas was filed for approval in Europe in early May and in the US in July. We are also very pleased to have agreed with Forest Laboratories on the US commercialisation of Daxas. We believe they are the best partner for Nycomed in this key market.

“Despite the global downturn and currency effects, Nycomed delivered a solid performance in the first half year, sustaining its momentum, he added.